Transplant News and Research

RSS

Cyclopamine may protect cholestatic livers from damage after transplant procedure

New research raises the possibility that the critically short supply of livers for organ donation could be expanded by treating so-called "marginal" livers with a substance that protects them from damage after being connected to recipients' blood supplies.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

1 Jun 2011

Nighttime heart and lung transplants do not affect patient survival

Despite concerns that surgeon fatigue is leading to dangerous complications for patients and data showing worse outcomes for many patients who undergo surgery at night, new Johns Hopkins research suggests that — in the case of heart and lung transplants — time of day has no affect on patient survival.

1 Jun 2011

Breast fat transfer procedure can achieve twofold increase in breast size

A plastic surgery procedure in which the patient's own fat is transplanted to the breasts—used along with treatment to expand the breast tissue before surgery—can achieve up to a twofold increase in breast size, according to a study in the June issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

1 Jun 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

After years of building hope for a treatment, Rochester researchers and clinicians will begin the first controlled clinical trial for Juvenile Batten disease this summer, thanks to $1 million in grants from the Food and Drug Administration and the Batten Disease Support and Research Association.

1 Jun 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune and cancer diseases, will present pre-clinical data on vidofludimus - its lead small-molecule drug candidate against autoimmune diseases - in systemic lupus erythematosus at EULAR 2011, Europe's largest scientific conference on rheumatic diseases, in London, UK, from May 25-28, 2011.

27 May 2011

Tacrolimus prevents breast cancer growth in pre-clinical studies

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th PLoS ONE.

27 May 2011

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Amylin Pharmaceuticals, Inc. today announced that the United States District Court for the Southern District of California issued a temporary restraining order (TRO) against Eli Lilly and Company relating to its litigation with respect to the Amylin / Lilly diabetes collaboration agreement.

26 May 2011

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Apollo centre for liver disease and transplantation has completed 100 liver transplantations in less than 4 years with over 90% success rate, creating a milestone in the history of medicine.

25 May 2011

Researchers discover protein switch that can trigger heart failure

Researchers at the Peter Munk Cardiac Centre discovered a protein switch which can trigger a cascade of events leading to heart failure, pointing to a new direction for drug development.

24 May 2011

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

An antibody packaged with a potent chemotherapy drug to selectively destroy acute lymphoblastic leukemia (ALL) cells eradicated or greatly reduced the disease for 61 percent of 46 patients in a phase II study. It will be presented at the 47th annual meeting of the American Society of Clinical Oncology in Chicago June 3-7.

24 May 2011

HIV-infected donors present novel source of organs for HIV-infected transplant candidates

A new study published in the American Journal of Transplantation reveals that HIV-infected deceased donors represent a potentially novel source of organs for HIV-infected transplant candidates that could decrease waitlist deaths and even shorten the national waitlist.

23 May 2011

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver).

23 May 2011

Scientists direct embryonic, induced human stem cells to become astrocytes in lab dish

Pity the lowly astrocyte, the most common cell in the human nervous system. Long considered to be little more than putty in the brain and spinal cord, the star-shaped astrocyte has found new respect among neuroscientists who have begun to recognize its many functions in the brain, not to mention its role in a range of disorders of the central nervous system.

23 May 2011

Gen-Probe seeks FDA regulatory clearance for PANTHER fully automated and integrated molecular testing system

Gen-Probe Incorporated announced today that the Company has filed a 510(k) application with the US Food and Drug Administration for its PANTHER system, a fully automated and integrated molecular testing system designed with the flexibility to handle a wide range of testing needs.

20 May 2011

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.

20 May 2011

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

Isis Pharmaceuticals, Inc. announced today that it has earned a $5 million milestone payment from GlaxoSmithKline related to the initiation of a Phase 1 clinical study for ISIS-TTRRx.

19 May 2011

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells - also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate.

19 May 2011

Treadmill test helps predict lifetime risk of cardiovascular disease in middle-age people

In two separate studies, UT Southwestern Medical Center researchers have found that how fast a middle-age person can run a mile can help predict the risk of dying of heart attack or stroke decades later for men and could be an early indicator of cardiovascular disease for women.

19 May 2011

Transplant News and Research

Cyclopamine may protect cholestatic livers from damage after transplant procedure

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Nighttime heart and lung transplants do not affect patient survival

Breast fat transfer procedure can achieve twofold increase in breast size

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

Tacrolimus prevents breast cancer growth in pre-clinical studies

U.S. District Court grants temporary restraining order in Amylin's litigation against Lilly

Apollo completes 100 liver transplantations in less than 4 years with over 90% success rate

Researchers discover protein switch that can trigger heart failure

Inotuzumab ozogamicin achieves over 50% response rate against acute lymphoblastic leukemia

HIV-infected donors present novel source of organs for HIV-infected transplant candidates

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Scientists direct embryonic, induced human stem cells to become astrocytes in lab dish

Gen-Probe seeks FDA regulatory clearance for PANTHER fully automated and integrated molecular testing system

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Isis receives $5M milestone payment from GSK for initiating ISIS-TTRRx Phase 1 study

New technique offers successful bone marrow, organ transplant for patients with autoimmune diseases

Treadmill test helps predict lifetime risk of cardiovascular disease in middle-age people

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News